Article
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Cancer - 15 Oct 2011
Sawaki Akira, Nishida Toshirou, Doi Toshihiko, Yamada Yasuhide, Komatsu Yoshito, Kanda Tatsuo, Kakeji Yoshihiro, Onozawa Yusuke, Yamasaki Makoto, Ohtsu Atsushi
Abstract excerpt
BACKGROUND: Patients with gastrointestinal stromal tumors (GISTs) resistant to both imatinib and sunitinib have a poor prognosis and few therapeutic options. In this study, the efficacy and safety of nilotinib (AMN107) as a third-line therapy for patients with GISTs was evaluated. METHODS: A single-arm, open-label trial was conducted in 8 Japanese hospitals. The key eligibility criteria included resistance or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.